- Home
- DERM
as 07-11-2025 4:00pm EST
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SCOTTSDALE |
| Market Cap: | 181.0M | IPO Year: | 2021 |
| Target Price: | $9.00 | AVG Volume (30 days): | 179.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.54 - $8.25 | Next Earning Date: | 08-11-2025 |
| Revenue: | $56,243,000 | Revenue Growth: | -29.69% |
| Revenue Growth (this year): | 28.99% | Revenue Growth (next year): | 52.61% |
Stock Insider Trading Activity of Journey Medical Corporation (DERM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Maraoui Claude | DERM | President & CEO | May 2 '25 | Sell | $6.84 | 4,834 | $33,064.56 | 2,348,313 | |
| Benesch Joseph | DERM | CFO | May 2 '25 | Sell | $6.84 | 2,409 | $16,477.56 | 203,557 | |
| Alloush Ramsey | DERM | COO | May 2 '25 | Sell | $6.84 | 2,857 | $19,541.88 | 504,817 |
Latest Journey Medical Corporation News
DERM Breaking Stock News: Dive into DERM Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
Journey Medical to Join Russell 2000, Russell 3000 Indexes
GlobeNewswire
18 days ago
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
TipRanks
21 days ago
Journey Medical announces data analysis from Phase 3 trials of Emrosi
GlobeNewswire
22 days ago
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
GlobeNewswire
a month ago
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
Yahoo Finance Video
a month ago
Will Tesla have to play catch up to Waymo's robotaxis?
Yahoo Finance
a month ago
Why Scott Bessent wants to make it easier for banks to own Treasurys
GlobeNewswire
a month ago
EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry
Compare DERM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DERM Journey Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.